Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
4.19 USD +2.44% Intraday chart for Monte Rosa Therapeutics, Inc. +1.70% -25.84%
May. 30 Monte Rosa Therapeutics Names Three Insiders to Leadership Team MT
May. 30 Monte Rosa Therapeutics, Inc. Announces Executive Promotions CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Monte Rosa Therapeutics Announces Leadership Team Promotions
AQ
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
AQ
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Inhibits Disease Progression in a T cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression
PU
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
AQ
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
AQ
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
AQ
Monte Rosa Therapeutics : Corporate Presentation - May 2024
PU
Monte Rosa Therapeutics: Q1 Earnings Snapshot
AQ
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
AQ
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer
PU
Monte Rosa Therapeutics: Q4 Earnings Snapshot
AQ
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
AQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
AQ
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
AQ
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
AQ
Monte Rosa Therapeutics: Q3 Earnings Snapshot
AQ
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. News Monte Rosa Therapeutics, Inc.
  5. Press Releases